Aug. 11 at 1:18 AM
$IMMX
SYSTEMIC SCLEROSIS DD — credit to Mungermind for uncovering this trail.
Systemic sclerosis/scleroderma is a rare, potentially fatal autoimmune disease in which abnormal antibodies drive blood-vessel damage and progressive scarring of the skin, lungs, heart and kidneys. There is NO cure.
Current care primarily consists of chronic immunosuppression—mycophenolate, cyclophosphamide or off-label rituximab—plus tocilizumab/nintedanib for lung disease, organ-specific drugs and high-risk stem-cell transplantation for select severe patients.
CAR-T competition validates the opportunity:
🔥
$CABA rese-cel: 5/6 patients reached rCRISS-25 and 4/6 reached rCRISS-50
🔥
$KYTX: Phase 1/2 KYV-101 trial
🔥
$NVS: randomized Phase 2 CAR-T trial versus rituximab
Most competing programs target CD19 on B cells.
Here is the overlooked IMMX angle: HBI0101 = NXC-201, and the autoimmune study was funded by Immix. NXC-201 targets BCMA on the deeper plasma-cell “antibody factories” responsible for producing destructive autoantibodies.
In the peer-reviewed report:
🔥 ALL 3 systemic-sclerosis patients improved in skin involvement and disease-activity measures
🔥 Lupus activity fell to ZERO in 2/3 patients and to 4 in the third
🔥 No ICANS/neurotoxicity across all 6 patients
🔥 Early safety was considered acceptable
Approximately 88,000 Americans have systemic sclerosis. If only 10% of that population ultimately became eligible for CAR-T, that would represent roughly 8,800 U.S. patients. At an illustrative
$300K–
$500K per one-time treatment, the initial prevalent opportunity alone could approach
$2.6B–
$4.4B—before new patients and international markets.
Scleroderma has not officially been confirmed as IMMX’s lead autoimmune indication. But the human results, expanding 120-patient autoimmune basket trial, Sheba activity and IMMX’s promise of “initial clinical data in other serious diseases” make this far more than a laboratory theory.
AL amyloidosis could prove NXC-201.
Autoimmune disease could reveal the platform. 🔥🚀
